Radiology and Oncology

When NSC 631570 has been used in clinic, it was observed that the patients treated with this drug tolerate the concomitant radiotherapy much better. The adverse effects of this aggressive treatment modality were significantly reduced to minimal. This gave reason to study radioprotective properties of NSC 631570 in the in vitro and in vivo tests. The radioprotective effect of NSC 631570 has been confirmed by the infection models in mice where its effect was superior to the effect of the known radioprotector Cysteamine. Compared to other agents, NSC 631570 exerted a strong radioprotective effect similar to such of lymphokinin. These radioprotective properties of NSC 631570 were confirmed in further studies in rats at the Institute of Applied Cell Culture (Munich, Germany). Ukrain normalized the level of nuclear thyroid hormone receptors influenced by short-term, whole body gamma-irradiation of rats with 1 Gy, beginning from the first day after administration of the drug. Thus, authors concluded Ukrain can minimize the consequences of irradiation on the endocrine system of experimental animals. The radio protective effect of NSC 631570 was also studied and confirmed on in vitro models on the human skin firbroblasts HSF1 and HSF2 as well as lung fibroblasts CCD32-LU. Differential effects of NSC 631570 in modulating radiation toxicity of human cancer cell lines and its protective effect in normal human fibroblasts suggest that this agent may be beneficial for clinical radiochemotherapy